Ocugen Inc
OCGN1.330USD
0.0000.00%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
415.39M시가총액
손실P/E TTM
자세한 내용은 Ocugen Inc 회사
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen Inc 정보
종목 코드 OCGN
회사 이름Ocugen Inc
상장일Dec 03, 2014
CEOMusunuri (Shankar)
직원 수95
유형Ordinary Share
회계 연도 종료Dec 03
주소11 Great Valley Parkway
도시MALVERN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호19355
전화14843284701
웹사이트https://ocugen.com/
종목 코드 OCGN
상장일Dec 03, 2014
CEOMusunuri (Shankar)
Ocugen Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.17M
+117.00%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
+153362.00%
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
209.10K
+207300.00%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
수익 분석
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2021
FY2020
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
United States
1.75M
0.00%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, Jan 18
마지막 업데이트: Sun, Jan 18
주주
주주 유형
주주
주주
비율
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
기타
84.82%
주주
주주
비율
Janus Henderson Investors
6.10%
The Vanguard Group, Inc.
5.02%
UBS Financial Services, Inc.
1.43%
Musunuri (Shankar Ph.D)
1.36%
Millennium Management LLC
1.27%
기타
84.82%
주주 유형
주주
비율
Investment Advisor
9.45%
Investment Advisor/Hedge Fund
8.28%
Hedge Fund
3.73%
Individual Investor
2.09%
Research Firm
0.47%
Corporation
0.35%
Venture Capital
0.14%
Bank and Trust
0.05%
기타
75.44%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
260
72.72M
22.18%
+8.84M
2025Q3
255
51.36M
16.44%
-32.04M
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
2023Q3
314
37.28M
14.69%
-34.75M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Janus Henderson Investors
20.00M
6.4%
+19.70M
+6514.39%
Nov 28, 2025
The Vanguard Group, Inc.
15.22M
4.87%
+450.90K
+3.05%
Sep 30, 2025
UBS Financial Services, Inc.
841.04K
0.27%
+438.31K
+108.83%
Sep 30, 2025
Musunuri (Shankar Ph.D)
1.34M
0.46%
+607.32K
+82.50%
Apr 14, 2025
Millennium Management LLC
4.16M
1.33%
-896.78K
-17.73%
Sep 30, 2025
GMT Capital Corp.
4.15M
1.33%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
1.23%
-1.36M
-26.19%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.68M
1.18%
+189.39K
+5.43%
Sep 30, 2025
Citadel Advisors LLC
1.57M
0.5%
+966.20K
+160.49%
Sep 30, 2025
State Street Investment Management (US)
1.36M
0.43%
+16.46K
+1.23%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Invesco NASDAQ Future Gen 200 ETF
0.82%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
더 보기
Invesco NASDAQ Future Gen 200 ETF
비율0.82%
Pacer WealthShield ETF
비율0%
iShares Russell 2000 ETF
비율0%
iShares Micro-Cap ETF
비율0%
ProShares UltraPro Russell2000
비율0%
ProShares Hedge Replication ETF
비율0%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
iShares Russell 2000 Growth ETF
비율0%
Global X Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
